The effect of GBT440 on cerebral perfusion and oxygenation (GBT440-MRI side study)
Withdrawn
- Conditions
- Sickle cell disease10018911
- Registration Number
- NL-OMON46527
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. Subjects have to be included in the HOPE study (GBT440-031 - NL60453.018.17)
Exclusion Criteria
1. Subjects who are excluded from the HOPE study (GBT440-031 - NL60453.018.17)
2. No informed consent has been given
3. Contra-indication for MRI or acetazolamide
4. Previous symptomatic stroke
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>In our current research we have shown that low hemoglobin levels raise resting<br /><br>CBF and leave patients with inadequate CVR. Our hypothesis is that GBT440 will<br /><br>result in higher hemoglobin levels, reduced hemolysis and decreased sickling<br /><br>resulting in lower viscosity, reduced CBF and increased CVR. The effect on<br /><br>oxygen utilization is uncertain given the contrasting effects on circulating<br /><br>oxygen content versus high oxygen affinity, but will be investigated in<br /><br>parallel.</p><br>
- Secondary Outcome Measures
Name Time Method <p>nvt</p><br>